The PennZone

  • Home
  • Business
  • Non-profit
  • Entertainment
  • Real Estate
  • Construction
  • Education
  • Technology
  • Travel

GLP-1 DRUG LIRAGLUTIDE MAY PROTECT AGAINST DEMENTIA USA - English India - English MEXICO - Spanish
The PennZone/10277538

Trending...
  • R&B Artist Mike Davis Announces Debut Full-Length Album Full Circle, Releasing April 7
  • 300 Episodes. One Mission: Brother Marcus Ignites a Global Movement of Inspiration
  • Attorney Joseph C. Kreps Files Lawsuit to Stop Alabama State Board of Pharmacy's Unlawful "Revenue-First" Rulemaking
* A GLP ~ A new study presented at the Alzheimer's Association International Conference® (AAIC®) 2024 has revealed promising results for a drug that may slow cognitive decline in individuals with Alzheimer's disease. The Phase 2b clinical trial data, reported by researchers today in Philadelphia and online, suggests that a glucagon-like peptide-1 (GLP-1) drug can protect the brain and potentially reduce cognitive decline.

GLP-1 receptor agonists are drugs that mimic the natural hormone glucagon-like peptide released by the stomach after eating. These drugs are commonly used to manage diabetes, promote weight loss, and lower the risk of heart disease, stroke, and kidney disease. Previous research in animal models of Alzheimer's disease has shown that GLP-1 receptor agonists may have neuroprotective effects, reduce early forms of amyloid (a protein associated with Alzheimer's), normalize glucose processing in the brain, and improve memory and learning. The specific GLP-1 receptor agonist studied in this trial was liraglutide, manufactured by Novo Nordisk.

The new research presented at AAIC 2024 suggests that liraglutide may have a protective effect on the brains of individuals with mild Alzheimer's disease. After one year of treatment, those who received liraglutide showed an 18% reduction in cognitive decline compared to those who received a placebo. This was measured by slowing the shrinking of key areas of the brain responsible for memory, learning, language, and decision-making.

More on The PennZone
  • MainConcept and NETINT Bring VPU Acceleration to Easy Video API
  • Dr. Roxanne Contee Continues to Shine as a Powerhouse in Philadelphia Fashion, Media, and Community
  • Larry R. Wasion's Jump Gate 2: Teleporter Expands the Time Travel Universe with High-Stakes Action and Ethical Dilemmas
  • Bruce A. Rosenblat Releases A Pocket Full of Change, a Sharp, Thought-Provoking Book on Growth, Perspective, and Personal Change
  • Marcus Boyd Announces Upcoming Children's Book The Royal World of Autism and Expands His Global Advocacy for Autism Awareness

Maria C. Carrillo, Ph.D., chief science officer and medical affairs lead for the Alzheimer's Association, expressed hope for these findings: "We are in an era of unprecedented promise with new treatments in development that may slow or even prevent cognitive decline due to Alzheimer's disease." She also noted that repurposing drugs already approved for other conditions has advantages such as providing data from previous research and practical use.

The Alzheimer's Association has invested over $82 million in the Part the Cloud research grants program, which has supported 68 clinical trials targeting various compounds, including repurposed drugs, to address different aspects of the disease.

The ELAD trial, led by Prof. Paul Edison, M.D., Ph.D., from Imperial College London, included 204 patients with mild Alzheimer's disease from 24 clinics in the United Kingdom. The participants were randomly assigned to receive either a daily subcutaneous injection of up to 1.8 mg of liraglutide or a placebo for one year. Before and after the study, all patients underwent magnetic resonance imaging (MRI) to evaluate brain structure and volumes, glucose metabolism PET scans, and detailed memory testing.

More on The PennZone
  • Former Philly Athletes Support Special Needs, Local Woman at Foundation Golf Classic
  • Phuket Bike Week Rebrands as Hard Rock Cafe Phuket Bike Week Under Landmark 5-Year Partnership
  • L2 Aviation Appoints Tony Bailey as President and Chief Operating Officer
  • Pieter Bouterse Studio Founder to Retire After 40+ Years; Seeks Successor to Continue Legacy
  • #WeAreGreekWarriors Opening Reception Packs the House

While the primary endpoint of change in cerebral glucose metabolic rate was not met, the secondary endpoint of change in clinical and cognitive measures showed significant benefit for those who received liraglutide. Additionally, an exploratory endpoint of brain volume also showed statistically significant improvement.

Dr. Edison explained that the slower loss of brain volume seen in those who received liraglutide suggests that the drug may protect the brain similarly to how statins protect the heart. He also noted that further research is needed to fully understand how liraglutide works but suggested that it may reduce inflammation in the brain, lower insulin resistance, and improve communication between nerve cells.

In terms of cognitive function, researchers found that those who received liraglutide had an 18% slower decline compared to those who received a placebo. This was measured by a composite score of 18 different tests assessing memory, comprehension, language, and spatial orientation.

Overall, this study provides hope for potential new treatments for Alzheimer's disease and highlights the importance of repurposing drugs already approved for other conditions. Further research is needed to fully understand how liraglutide works and its potential as a treatment for Alzheimer's disease.
Filed Under: Business

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • 88% Revenue Growth; Charging Into the Future with Explosive Growth, Strategic EV Expansion and Infrastructure Dominance Signal a Breakout Opportunity
  • Forge Resources Unlocks Major Gold-Copper System in Yukon as Drilling Success and Strategic Assets Fuel High-Impact Growth Story for: $FRGGF
  • Game Day Private Jets Launches REVUP Platform to Transform Fan & Donor Travel Into a Revenue Engine for College Athletics
  • Heritage at South Brunswick Team Celebrates Major Wins at NJBA Sales and Marketing Awards
  • Girl Scouts of Eastern Pennsylvania's "Summer of Sisterhood" Offers Two Lehigh Valley-based Camps
  • Girl Scouts of Eastern Pennsylvania's "Summer of Sisterhood" Returns to Camp Valley Forge
  • Best Companies Group Launches Best Places to Work in Maine Program
  • InterMountain Announces the Opening of TownePlace Suites Reno
  • SnapTax Launches AI-Powered Tax Planning Platform for Freelancers and 1099 Workers — Now Free for 90 Days
  • MAG Magna Corp Targets Trillion-Dollar Opportunity by Tokenizing Rare Earth Assets Critical to AI, EVs, & Defense: MAG Magna Corp.: Stock Symbol: MGNC
  • A.M. Logging Highlights Essential Landscaping Supplies for Spring Projects in Central Pennsylvania
  • Congressional Roundtable Exposes Mental Health Crisis: More Spending and Treatment, Worse Results – CCHR Demands Accountability
  • Attorney Joseph C. Kreps Files Lawsuit to Stop Alabama State Board of Pharmacy's Unlawful "Revenue-First" Rulemaking
  • NAIDOC Week Australia 2026 | 50 Years Deadly - Celebrates Culture, Resilience, and Global Connection
  • Solo Researcher Builds Three Novel AI Architectures From Scratch, Including Post-Transformer Model
  • JBlair Communications Launches "NextLevel Spotlight" to Elevate High School/Collegiate Athletes
  • R&B Artist Mike Davis Announces Debut Full-Length Album Full Circle, Releasing April 7
  • Aurelius Dunbar Earns Prestigious NWCA NCAA Div. I Scholar All-American Honors for 2025-2026 Season
  • Second Annual "Autism In Bloom" Event By D&D Journey Promotes Autism Awareness Month
  • PlanetAI Nature Space (PNS), certificadora Europea, lanza su plataforma EUDR-PNS Ready basada en IA, satélites y trazabilidad blockchain

Popular on PennZone

  • Registered Nurse Launches Healthcare Wealth Strategy Practice for Healthcare Professionals - 139
  • Actress/Model Raelia Lewis Building a Powerful Name in Entertainment and Fashion
  • R&B Artist Mike Davis Announces Debut Full-Length Album Full Circle, Releasing April 7
  • New Book Warring From the Standpoint of the Throne Room Calls Believers to Pray From Victory
  • 300 Episodes. One Mission: Brother Marcus Ignites a Global Movement of Inspiration
  • Conexwest: Shipping Containers Are Powering the Next Generation of Bitcoin Mining Infrastructure
  • New Report Reveals Surprising Trends in Ohio Airport Accidents
  • The "Unsexy" Business Quietly Creating 130+ New Entrepreneurs Across America — From Alaska to Puerto Rico
  • Bethany Nikitenko Elected Board Vice President of Philadelphia VIP
  • ASI Hosts 2026 Executive Business Summit for Global Partner Community

Similar on PennZone

  • Bruce A. Rosenblat Releases A Pocket Full of Change, a Sharp, Thought-Provoking Book on Growth, Perspective, and Personal Change
  • Pieter Bouterse Studio Founder to Retire After 40+ Years; Seeks Successor to Continue Legacy
  • Special Alert! Highly Undervalued Stock: $317M Revenue in 2025 for Telecom Leader IQSTEL, Inc. (N A S D A Q: IQST)
  • Igniting High-Growth Transformation With Launch of XMax AI Subsidiary, Leveraging Global Furniture Dominance to Enter Explosive AI Markets: XMax Inc
  • Acuvance Earns 2026 Great Place to Work® Certification
  • As Global Tensions Rise, Demand Grows for Private Spaces to Process Thoughts and Speak Freely Online
  • Riggo Production Studio Launches Monthly Content Package for Growing Brands
  • Accelerating into Active Oil Production with over 100 Barrels per day now being produced as Dual-revenue engine begins Generating Cash Flow: $IBG
  • 88% Revenue Growth; Charging Into the Future with Explosive Growth, Strategic EV Expansion and Infrastructure Dominance Signal a Breakout Opportunity
  • Forge Resources Unlocks Major Gold-Copper System in Yukon as Drilling Success and Strategic Assets Fuel High-Impact Growth Story for: $FRGGF
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us